Abstract:Extracellular vesicle and clustered‐regularly interspaced short palindromic repeats gene editing mediated treatment approaches used mouse and patient‐derived cell line as models. With this treatment, an increase in motor coordination and immunomodulation and a decrease in striatal atrophy and neuronal death were observed. Neurodegenerative diseases are characterized by progressive deterioration of the nervous system. Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) are prominently life‐threatening examples of neurodegenerative diseases. The complexity of the pathophysiology in neurodegenerative diseases causes difficulties in diagnosing. Although the drugs temporarily help to correct specific symptoms including memory loss and degeneration, a complete treatment has not been found yet. New therapeutic approaches have been developed to understand and treat the underlying pathogenesis of neurodegenerative diseases. With this purpose, clustered‐regularly interspaced short palindromic repeats/CRISPR‐associated protein (CRISPR/Cas) technology has recently suggested a new treatment option. Editing of the genome is carried out by insertion and deletion processes on DNA. Safe delivery of the CRISPR/Cas system to the targeted cells without affecting surrounding cells is frequently investigated. Extracellular vesicles (EVs), that is exosomes, have recently been used in CRISPR/Cas studies. In this review, CRISPR/Cas and EV approaches used for diagnosis and/or treatment in AD, PD, ALS, and HD are reviewed. CRISPR/Cas and EV technologies, which stand out as new therapeutic approaches, may offer a definitive treatment option in neurodegenerative diseases.

Extracellular vesicle and CRISPR gene therapy: Current applications in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease

Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders

Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders

Application of CRISPR/Cas9 System in the Treatment of Alzheimer's Disease and Neurodegenerative Diseases

Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders

Prevention and Treatment of Alzheimer's Disease Through CRISPR/Cas Technology

CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics

In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification

Clustered Regularly Interspaced Short Palindromic Repeats As an Advanced Treatment for Parkinson's Disease

Neural Stem Cell-Derived Extracellular Vesicles Mitigate Alzheimer’s Disease-Like Phenotypes in a Preclinical Mouse Model

The Application of CRISPR/Cas9 Technology in Neurological Diseases

Role of extracellular vesicles in neurodegenerative diseases

CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease

CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics

The Molecular Efficacy of CRISPR-Cas9 in TreatingAlzheimer’s Disease

Engineering extracellular vesicles for Alzheimer's disease: An emerging cell-free approach for earlier diagnosis and treatment.

Vector enabled CRISPR gene editing – A revolutionary strategy for targeting the diversity of brain pathologies

Emerging Gene Therapies for Alzheimer's and Parkinson's Diseases: An Overview of Clinical Trials and Promising Candidates

CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis

An Emerging Therapeutic Strategy for Challenging Neurodegenerative Diseases

Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease